Word note · GHK-Cu
First, find out which form is being offered: a skin product or an injection. Keep that answer in view while reading any claim about it.
GHK is a peptide made of three amino acids, the small parts used to build proteins. When copper attaches to GHK, the substance is called GHK-Cu. A label may call this same ingredient copper tripeptide-1.
Source to readFDA and NIH substance-name record
A substance-name record identifies an ingredient. Ask separately about the finished product.
A cosmetic changes appearance, such as a skin product sold for that purpose. These products generally did not need FDA approval before sale, except for colour additives, at the September 30, 2026 check.
Source to readFDA authority over cosmetics
FDA is the US Food and Drug Administration. A skin-product claim to treat an illness, or to alter the way a body functions, could put it under drug law. That distinction was checked September 30, 2026.
GHK-Cu had no approved medicine, including no approved shot, in the FDA records checked September 30, 2026.
Source to readFDA approval-record search
A claim about a cream does not answer a question about an injection.
Studies in people were notably scarce for GHK-Cu wrinkle products, according to a review published in 2025.
Source to readReview in Bioimpacts
A shortage of research leaves the answer uncertain. It does not prove that a product cannot work.
No study testing GHK-Cu shots in people turned up in the ClinicalTrials.gov search dated September 30, 2026.
Source to readUS trial-register search
That is a finding from this register on that date, rather than a survey of all research everywhere.
The groups seeking to add GHK-Cu as an injection ingredient to FDA's compounding list took their requests back. On the FDA page with an April 22, 2026 content date, the injection entry is headed “nominated but withdrawn”.
Source to readFDA entry for injectable GHK-Cu
Taking back the requests gave no permission to compound the injection and did not clear it for use, as checked September 30, 2026. Ask the pharmacy to explain the legal basis for the exact shot being offered; this entry does not supply one.
For GHK-Cu used without injection, FDA is still considering whether to add the ingredient to its compounding list. Its list updated May 14, 2026 puts this use in Category 1, meaning the group under review.
Source to readFDA category list
FDA's temporary policy is to hold back action over use of a Category 1 ingredient when the pharmacy satisfies the guidance's conditions. This is about when FDA plans to enforce its ingredient-list rule. Other requirements still include a prescription naming the patient and restrictions on copying a medicine already sold. The temporary policy is not approval or a guarantee that a particular preparation is lawful, as checked September 30, 2026. Ask the pharmacy to show how its product meets each condition; the list alone cannot answer that.
FDA warns of two possible problems with GHK-Cu shots: peptide parts may clump together, or unwanted peptide material may be present. These could make the body's defences react against the substance. Human safety information was limited at the September 30, 2026 check.
Source to readFDA concern and its limits
This is a concern about the injected preparation. The FDA entry does not say whether clumps form before or after injection, or how often harm occurs.